ClinicalTrials.Veeva

Menu

Safety and Immunogenicity of a Booster Vaccination With an Adapted Vaccine

H

Hipra

Status and phase

Active, not recruiting
Phase 3
Phase 2

Conditions

SARS-CoV2 Infection

Treatments

Biological: PHH-1V81
Biological: Comirnaty Omicron XBB1.5

Study type

Interventional

Funder types

Industry

Identifiers

NCT06181292
HIPRA-HH-14

Details and patient eligibility

About

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate against SARS-CoV-2 developed by HIPRA (PHH-1V81).

Full description

This is a phase IIb/III, double-blind, randomised, active-controlled, multi-centre, non-inferiority clinical trial that aims to determine safety, tolerability and immunogenicity of a booster vaccination with a recombinant protein receptor binding domain (RBD) fusion homodimer of XBB.1.16 adapted candidate against SARS-CoV-2 developed by HIPRA (PHH-1V81).

Approximately 612 participants who have received a primary scheme with an EU-approved mRNA vaccine (two doses) and at least one booster dose of an EU-approved mRNA vaccine against COVID-19, will be randomly assigned to the following two treatment arms in a PHH-1V81 : Comirnaty (Omicron XBB.1.5) 2:1 ratio:

PHH-1V81 vaccine arm: Approximately 408 adults will receive a booster dose of PHH-1V81 (HIPRA adapted vaccine). Comirnaty vaccine arm: Approximately 204 adults will receive a booster dose of Comirnaty Omicron XBB.1.5.

Participants will be stratified before randomisation by age group (approximately 10% of adults ≥60 years old), and by number of doses previously received.

All participants will receive a booster dose of PHH-1V81 or Comirnaty Omicron XBB.1.5 at Day 0 and will be followed for 6 months. All subjects will be closely observed for 15 minutes after vaccination on site.

Enrollment

612 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Adults aged 18 or older at Day 0
  • Are willing and able to sign the informed consent and can comply with all study visits and procedures
  • Participant must have received a primary scheme of an EU-approved mRNA vaccine (2 doses) and at least one booster dose with an EU-approved mRNA vaccine. Last booster dose must have been administered at least 6 months before Day 0.
  • Having a negative Rapid Antigen Test for COVID-19 at Day 0 prior to vaccination.
  • Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-immunocompromised), if these are stable and well-controlled according to the investigator's judgment.
  • Uses an accepted method of contraception

Exclusion criteria

  • Participant with an acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator
  • Participant with a medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Participant with history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention
  • Immunocompromised individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than steroids and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination
  • Participant with a bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection
  • Have receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months
  • Participation in other studies involving study intervention if last dose is within 28 days prior to screening and/or it is planned to receive during study participation
  • Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening
  • Received any COVID-19 vaccines other than EU-approved mRNA vaccines
  • Received any Omicron XBB adapted vaccine before Day 0
  • COVID-19 infection diagnosed in the previous 6 months before Day 0. History of COVID-19 infections is allowed
  • History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

612 participants in 2 patient groups

PHH-1V81
Experimental group
Description:
One dose of 40ug of PHH-1V81, administered intramuscularly
Treatment:
Biological: PHH-1V81
Comirnaty Omicron XBB1.5
Active Comparator group
Description:
One dose of 30ug of Comirnaty Omicron XBB1.5, administered intramuscularly
Treatment:
Biological: Comirnaty Omicron XBB1.5

Trial contacts and locations

10

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems